Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.41B |
| 2 |
ExxonMobil
XOM
|
+$937M |
| 3 |
Eli Lilly
LLY
|
+$875M |
| 4 |
Tesla
TSLA
|
+$749M |
| 5 |
GE Aerospace
GE
|
+$740M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$1.99B |
| 2 |
Deutsche Bank
DB
|
+$1.49B |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$1.12B |
| 4 |
Broadcom
AVGO
|
+$1.12B |
| 5 |
Amgen
AMGN
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.51% |
| 2 | Healthcare | 16.3% |
| 3 | Consumer Discretionary | 11.31% |
| 4 | Industrials | 10.9% |
| 5 | Financials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Weatherford International
WFRD
$6.57B
| $99.5M | 0.03% |
4,697,823
-28,424
| -0.6% | -$905K |
|
277
Globus Medical
GMED
$11.5B
| $99.4M | 0.03% |
1,770,315
-130,799
| -7% | -$8.6M |
|
278
Freshpet
FRPT
$3.47B
| $97.4M | 0.03% |
1,877,615
-1,273,931
| -40% | -$98.3M |
|
279
Chegg
CHGG
$85.3M
| $97.2M | 0.03% |
5,177,591
+1,012,561
| +24% | +$23.2M |
|
280
Credo Technology Group
CRDO
$51.5B
| $96.1M | 0.03% |
8,750,082
| – | – |
|
281
US Bancorp
USB
$102B
| $92.3M | 0.03% |
2,005,972
-3,414,323
| -63% | -$170M |
|
282
TPG
TPG
$8.35B
| $90.7M | 0.03% |
3,791,621
+1,683
| +0% | +$45.4K |
|
283
International Flavors & Fragrances
IFF
$21.5B
| $90.1M | 0.03% |
+756,732
| New | +$94.6M |
|
284
XP
XP
$8.06B
| $89.7M | 0.03% |
4,993,472
-9,859,394
| -66% | -$227M |
|
|
CCC
285
CCC Intelligent Solutions
CCC
$4.01B
| $89.1M | 0.03% |
9,683,540
+1,632
| +0% | +$15K |
|
286
Extra Space Storage
EXR
$31.4B
| $88.9M | 0.03% |
+522,382
| New | +$96.8M |
|
287
Petrobras
PBR
$115B
| $87.9M | 0.03% |
7,527,433
-20,783,512
| -73% | -$288M |
|
288
Restaurant Brands International
QSR
$26.7B
| $87.3M | 0.03% |
+1,741,569
| New | +$93.2M |
|
289
Guardant Health
GH
$21.6B
| $86.7M | 0.03% |
2,149,333
-1,860,172
| -46% | -$92.2M |
|
|
SBNY
290
DELISTED
Signature Bank
SBNY
| $84.9M | 0.03% |
473,860
+113,948
| +32% | +$25.5M |
|
|
GDEN
291
DELISTED
Golden Entertainment
GDEN
| $84.3M | 0.03% |
2,131,300
+65,200
| +3% | +$3.07M |
|
292
Willis Towers Watson
WTW
$31B
| $83.7M | 0.03% |
424,248
| – | – |
|
293
Trane Technologies
TT
$106B
| $83.5M | 0.03% |
+642,608
| New | +$88.9M |
|
294
Novartis
NVS
$290B
| $83.2M | 0.03% |
984,751
-363
| -0% | -$31.8K |
|
|
SKX
295
DELISTED
Skechers
SKX
| $80.1M | 0.02% |
2,250,000
+50,000
| +2% | +$1.92M |
|
296
NCR Voyix
VYX
$1.13B
| $79.3M | 0.02% |
4,155,278
+163,163
| +4% | +$3.48M |
|
297
Coupang
CPNG
$29B
| $79M | 0.02% |
6,192,805
+793,898
| +15% | +$10.8M |
|
298
Extreme Networks
EXTR
$3.22B
| $77.7M | 0.02% |
8,705,375
-2,350,000
| -21% | -$23.9M |
|
|
GTLS
299
DELISTED
Chart Industries
GTLS
| $75.2M | 0.02% |
449,280
+194,280
| +76% | +$33.2M |
|
300
Coursera
COUR
$1.49B
| $69.5M | 0.02% |
4,902,442
-2,350,656
| -32% | -$41.9M |
|
Similar funds
Capital Research Global Investors's Q2 2022 Portfolio in Review
As of Q2 2022, Capital Research Global Investors held 461 positions worth $321B, down 21% from $405B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Capital Research Global Investors withdrew a net $12.2B in Q2 2022, closing 38 positions and reducing 158 holdings. Its most notable exit was Deutsche Bank, an estimated $1.49B position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Capital Research Global Investors opened a new position in Eli Lilly worth $945M.
- Capital Research Global Investors's largest Q2 2022 buy was Eli Lilly: 2,914,107 shares worth $945M.
- Capital Research Global Investors added most to AbbVie in Q2 2022, an estimated $1.41B increase.
- Capital Research Global Investors's biggest Q2 2022 reduction was JPMorgan Chase, cutting an estimated $1.99B.
- Capital Research Global Investors fully exited Deutsche Bank in Q2 2022, selling an estimated $1.49B.
- Capital Research Global Investors's ten largest holdings make up 29% of its $321B portfolio in Q2 2022.
- Capital Research Global Investors opened 21 new positions and closed 38 in Q2 2022.
- Capital Research Global Investors's portfolio value fell 21% quarter-over-quarter to $321B.
Based on Capital Research Global Investors's 13F filing for Q2 2022, filed 15 Aug 2022.